Oncothyreon Inc. lost more than half its value during early trading last Wednesday after partner Merck KgaA disclosed that its cancer vaccine, L-BLP25 (Stimuvax), failed to meet the primary endpoint of overall survival in a pivotal Phase III trial in non-small-cell lung cancer. Read More
Top-line data from three Phase III trials of simeprevir (TMC435) in patients with hepatitis C virus (HCV) genotype 1 infection appear to confirm what Medivir AB has always maintained – that it has a potentially best-in-class protease inhibitor on its hands. Read More
In a discovery that has important implications for the future of HIV therapy, an international team of researchers has identified the molecule by which the virus enters the immune cells known as dendritic cells. Read More
A third spinout has emerged from GlaxoSmithKline plc's neurosciences research portfolio, with the formation of NeRRe Therapeutics Ltd. The new company begins life with a portfolio of four neurokinin-1 receptor antagonists – of which two are ready for Phase II – and £11.5 million (US$18.7 million) in venture capital funding. Read More
Karolinska Development AB is getting an SEK220 million ($33.7 million) cash injection from Rosetta Capital Ltd. for 13 of the 25 companies in its portfolio. Read More
Poxel SA raised €13 million (US$17.3 million) in a Series B round that is intended to see its lead Type II diabetes treatment, imeglimin, through Phase IIb and into the arms of a commercialization partner. Read More
• Amarin Corp. plc, of Dublin, Ireland, submitted a supplemental new drug application (sNDA) to the FDA seeking approval for Chemport Inc. as an additional active pharmaceutical ingredient supplier for Vascepa (icosapent ethyl). Read More
